Oxeia Biopharmaceuticals
Rest is not enough
RICHARD SHERMAN, NFL All-Pro, Joins Oxeia Biopharmaceuticals Advisory Board

San Diego, CA – Oxeia Biopharmaceuticals Inc. announces Richard Sherman, cornerback of the Seattle Seahawk’s (National Football League), as a member of its Advisory Board.

“Richard is a passionate advocate for brain health and a star on and off the field. As an active player in the NFL, Richard participates in a very rigorous concussion testing protocol each season. This direct experience will be invaluable to us as we enter clinical trials for our concussion drug treatment. We look forward to working closely with Richard,” said Kartik Shah, Chief Business Officer for Oxeia Biopharmaceuticals.

Mr. Sherman joins an experienced pharmaceutical development team at Oxeia that is advised by leading medical experts from Stanford, UCSD, Harvard and the Concussion Legacy Foundation. The company is preparing to initiate a phase 2 clinical study in concussion patients with OXE-103. OXE-103 is an agent with well-established neuroprotective properties with an extensive safety record.

“The Oxeia team is at the forefront of concussion treatment innovation. As a professional football player, I am acutely aware of the risk posed by concussions – we need to start talking about, and working actively on solutions. I look forward to assisting Oxeia as they develop an FDA-approvable treatment for concussions that is safe and effective,” said Mr. Sherman, cornerback, Seattle Seahawks.

Concussions induce a metabolic response within the brain resulting in an “energy crisis” as brain cells attempt to respond to the injury. Oxeia’s lead program, OXE-103, uniquely targets the metabolic dysfunction and subsequent neurotrauma underlying acute concussion pathophysiology. Oxeia anticipates initiating Phase 2 studies for OXE-103 in concussion and additional neurological indications in early 2018.

Please visit www.oxeiabiopharma.com for more information and contact details.

About Oxeia Biopharmaceuticals, Inc.
Oxeia Biopharmaceuticals, Inc. is a privately held clinical stage biotechnology company headquartered in San Diego, CA. The company is focused on developing treatments for concussions and other acute neurotrauma conditions.

Oxeia’s lead program, OXE-103, uniquely targets the metabolic dysfunction and subsequent neurotrauma underlying acute concussion pathophysiology. The program has maintained a strong safety profile across nine previous clinical studies totaling 345 patients.

About Richard Sherman
Born in Compton, California, Mr. Sherman excelled both on the field as a football and track star, and in the classroom as salutatorian with a 4.2 GPA at Dominguez High School. After a stellar career at Stanford University, the outstanding cornerback was picked by the Seattle Seahawks in the fifth round in the 2011 NFL Draft. Mr. Sherman anchored the defense and helped lead the Seahawks to back-to-back NFC Championships in 2013 and 2014, as well as their first NFL title in 2014. Mr. Sherman is a 4x Pro Bowler, 4x All-Pro, and took home the NFC Defensive Player of the Year title in 2014. Mr. Sherman has been an NFLPA Player Representative since September 2014.

Off the field, he started his charity – Blanket Coverage, The Richard Sherman Family Foundation – in 2013 in order to provide students in low-income communities with clothing and supplies to help them work towards achieving their goals. Mr. Sherman was nominated for the Walter Payton Man of the Year Award in 2015 because of his efforts in the community.

Kartik Shah, Chief Business Officer